The C282Y and H63D polymorphisms in the HFE gene have been implicated in susceptibility of breast cancer, but a number of studies have reported inconclusive results. The aim of this study is to investigate the association between the C282Y and H63D polymorphisms in the HFE gene and breast cancer risk by meta-analysis. We searched PubMed and Embase databases, covering all related studies until March 2, 2013. Statistical analysis was performed using STATA 10.0. A total of 7 studies including 1,720 cases and 18,296 controls for HFE C282Y polymorphism and 5 studies including 942 cases and 1,571 controls for HFE H63D polymorphism were included in the meta-analysis. The results showed that HFE C282Y polymorphism was significantly associated with increased risk of breast cancer under homozygotes vs. wild-type model (OR = 2.06, 95%CI = 1.19–3.58) and recessive model (OR = 1.98, 95%CI = 1.14–3.44) but not under heterozygotes vs. wild-type model (OR = 0.97, 95%CI = 0.70–1.35), dominant model (OR = 1.00, 95%CI = 0.72–1.40) and multiplicative model (OR = 1.04, 95%CI = 0.76–1.42). However, we did not find any association between HFE H63D polymorphism and breast cancer risk under all genetic models. This current meta-analysis suggested that C282Y polymorphism rather than H63D might be associated with increased risk of breast cancer.
HFE Polymorphism Breast cancer Meta-analysis
This is a preview of subscription content, log in to check access.
Conflicts of interest
Weinberg ED. The role of iron in cancer. Eur J Cancer Pre. 1996;5:19–36.Google Scholar
Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996;13:399–408.CrossRefPubMedGoogle Scholar
Beckman LE, Van Landeghem GF, Sikström C, Wahlin A, Markevärn B, Hallmans G, et al. Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders. Carcinogenesis. 1999;20:1231–3.CrossRefPubMedGoogle Scholar
Kallianpur AR, Hall LD, Yadav M, Byrne DW, Speroff T, Dittus RS, et al. The hemochromatosis C282Y allele: a risk factor for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;35:1155–64.CrossRefPubMedGoogle Scholar
Abraham BK, Justenhoven C, Pesch B, Harth V, Weirich G, Baisch C, et al. Investigation of genetic variants of genes of the hemochromatosis pathway and their role in breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1102–7.CrossRefPubMedGoogle Scholar
Kondrashova TV, Neriishi K, Ban S, Ivanova TI, Krikunova LI, Shentereva NI, et al. Frequency of hemochromatosis gene (HFE) mutations in Russian healthy women and patients with estrogen-dependent cancers. Biochim Biophys Acta. 2006;1762:59–65.CrossRefPubMedGoogle Scholar
Syrjäkoski K, Fredriksson H, Ikonen T, Kuukasjärvi T, Autio V, Matikainen MP, et al. Hemochromatosis gene mutations among Finnish male breast and prostate cancer patients. Int J Cancer. 2006;118:518–20.CrossRefPubMedGoogle Scholar
Osborne NJ, Gurrin LC, Allen KJ, Constantine CC, Delatycki MB, McLaren CE, et al. HFE C282Y homozygotes are at increased risk of breast and colorectal cancer. Hepatology. 2010;51:1311–8.CrossRefPubMedGoogle Scholar
Batschauer AP, Cruz NG, Oliveira VC, Coelho FF, Santos IR, Alves MT, et al. HFE, MTHFR, and FGFR4 genes polymorphisms and breast cancer in Brazilian women. Mol Cell Biochem. 2011;357:247–53.CrossRefPubMedGoogle Scholar
Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, D’Agostino Jr R, et al. An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res. 2011;71:6728–37.PubMedCentralCrossRefPubMedGoogle Scholar
Fargion S, Valenti L, Fracanzani AL. Hemochromatosis gene (HFE) mutations and cancer risk: expanding the clinical manifestations of hereditary iron overload. Hepatology. 2010;51:1119–21.CrossRefPubMedGoogle Scholar
Jin F, Qu LS, Shen XZ. Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: a meta-analysis. J Exp Clin Cancer Res. 2010;29:18.PubMedCentralCrossRefPubMedGoogle Scholar
Agudo A, Bonet C, Sala N, Muñoz X, Aranda N, Fonseca A., et al. Hemochromatosis (HFE) gene mutations and risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Carcinogenesis. 2013 Mar 5. doi:10.1093/carcin/bgt045.